Abstract 441: IL-17 and IL-17-producing cells associated with advanced stage or poor prognosis in oral cancers, through enhancing tumor progression

Abstract

Abstract Introduction: Interleukin 17 (IL-17) majorly produced by Th17 and Tc17 cells, contributes greatly in inflammatory associated diseases. However, its presence was reported to suppress tumor growth by enhancing cytotoxic T cell responses. On the contrary, through inducing angiogenesis, IL-17 appeared to promote tumor progression. Here we demonstrated IL-17 and their producing cells directly correlating with advanced stage or poor prognosis of oral cancer patients. Methods: Peripheral blood samples were obtained from the oral patients in Chang Gung Memorial Hospital, and the multi-color flow cytometric analysis and enzyme conjugated immunoassays were utilized to identify the IL-17 producing T cell subsets and to quantify the production of inflammation-associated cytokines. The effects of IL-17 on the growth and invasion of oral cancer cells were determined with the supplement with recombinant IL-17 (γhIL-17) and cell culture supernatant. Results: The significantly increased prevalence of IL-17-producing T cells was correlated with clinical stage and the patients’ peripheral blood mononuclear cells secreted higher amount of IL-17 and other related factors. Such responses also appeared to be associated with poor prognosis. Moreover, the stimulation of γhIL-17 apparently induced cell proliferation, migration and invasion in oral cancer cells, indicating that IL-17 directly contribute to tumor progression. Conclusion: These findings suggest IL-17 and its related factors are crucial to tumor development, and such responses may therefore lead to the clinical impact of advanced stage or poor prognosis in oral cancer. Citation Format: Meng Hua Lee. IL-17 and IL-17-producing cells associated with advanced stage or poor prognosis in oral cancers, through enhancing tumor progression. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 441. doi:10.1158/1538-7445.AM2015-441